Delphine Issard

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

Ludwig Kappos, Jens Kühle, Juha Multanen et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 84 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

Nicola De Stefano, Mark S. Freedman, Frederik Barkhof et al. · Journal of Neurology Neurosurgery & Psychiatry · 2016 · 40 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study

Nicola De Stefano, Maria Pia Sormani, Bettina Stubinski et al. · Journal of the Neurological Sciences · 2011 · 34 citations

Life Sciences, Neurology, Pharmacotherapy +11

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis

Nicola De Stefano, François Curtin, Bettina Stubinski et al. · Multiple Sclerosis Journal · 2010 · 34 citations

Life Sciences, Neurology, Pharmacotherapy +12

Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden

Katja M. Hakkarainen, Rosa Juuti, Sarah Burkill et al. · Therapeutic Advances in Neurological Disorders · 2020 · 32 citations · Full text

Public Health, Immunology, Obstetrics +13